OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Trading Down 3.6 %

OKUR opened at $4.78 on Wednesday. The firm has a market capitalization of $64.22 million, a price-to-earnings ratio of -0.39 and a beta of 0.28. The stock has a fifty day moving average price of $5.36. OnKure Therapeutics has a twelve month low of $4.45 and a twelve month high of $20.00.

Analyst Upgrades and Downgrades

OKUR has been the topic of several research analyst reports. HC Wainwright lowered their price target on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Leerink Partners started coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective on the stock. Leerink Partnrs raised shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, Oppenheimer lowered their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $32.33.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.